Applied Vascular Engineering (US) starts Micro Stent trial
This article was originally published in Clinica
Executive Summary
Applied Vascular Engineering (US) has started US trials of its Micro Stent following receipt of an Investigational Device Exemption from the FDA. SMART (Study of Micro Stent's Ability to Limit Restenosis Trial) will compare Micro Stent to J&J's Palmaz-Schatz stent in de novo lesions at 20 centres. Enrolment of patients is expected to take six months. Like the Benestent II heparin-coated stent trial (see Clinica No 669/70, p 24), SMART includes ticlopidine antiplatelet therapy in its protocol.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.